Sedation In Intubated Patients — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for sedation in intubated patients. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
6
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Sedation In Intubated Patients

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Roche) 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating sedation in intubated patients. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
28
2
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Versed
midazolam
 Generic (originally Roche) 6 61 — 2028-01-18

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9687495 Versed method of use 75 2028-01-18
9289432 Versed method of use 75 2028-01-18
8217033 Versed method of use 75 2028-01-18
8809322 Versed formulation 55 2028-01-18
10966990 Versed formulation 42 2038-06-20
10966990 Versed formulation 42 2038-06-20

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10966990 Versed formulation 42 2038-06-20
10966990 Versed formulation 42 2038-06-20
8809322 Versed formulation 55 2028-01-18
9687495 Versed method of use 75 2028-01-18
9289432 Versed method of use 75 2028-01-18
8217033 Versed method of use 75 2028-01-18

Related